Cancer Research UK is the world's largest charity dedicated to research on the causes_ treatment and prevention of cancer

Cancer+Research+Technology%0d%0a%0d%0aCancer+Research+Technology%0d%0aExploiting+Research+for+the+Benefit+of+Cancer+Patients%0d%0a%0d%0aCGC%2f+OOB+Course%0d%0a%0d%0a11th+May+2005%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aTechnology+Transfer+in+Practice+Exploiting+Research+for+the+Benefit+of+Patients%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aPresentation+Outline%0d%0a%0d%0a%e2%80%a2+What+is+technology+transfer%3f+What+models+can+be+adopted%3f+%e2%80%a2+Trends+in+the+pharmaceutical%2fbiotech+industry+%e2%80%a2+Trends+in+Commercial+deals+in+the+life+sciences+%e2%80%a2+How+can+Technology+Transfer+professionals+help+%e2%80%a2+Experiences+of+CRT%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0aTrack+Record+Development+Capabilities+Partnerships+with+Institutes+and+Charities%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhat+is+Technology+Transfer%3f%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0aThe+transfer+of+ideas+into+the+free+market+for+the+benefit+of+society+and+the+economy+Knowledge+Management+between+organisations+involved+in+a+development+chain+A+process+by+which+the+results+of+publically%2fcharitably+funded+research+are+transferred+to+industry+at+fair+market+rates+The+process+by+which+projects+are+developed+from+inception+to+market+through+a+range+of+partners.+A+system+to+protect+ideas+created+in+research+with+potential+applications+wider+than+the+basic+research.%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a%e2%80%a2%0d%0a%e2%80%a2%0d%0a%0d%0aAn+alternative+source+of+research+funding%3f%0d%0aA+lot+of+legal+jargon%2c+a+large+cost+and+a+lot+of+effort+for+very+little+to+show+for+it+9+times+out+of+ten!%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aTechnology+transfer%3a+What+is+it%3f%0d%0aIndustry%0d%0a%0d%0aProducts+Services%0d%0a%0d%0aDevelopment+Stage%0d%0a%0d%0aLow+innovation+%2b+high+cost%0d%0a%0d%0aLab%0d%0aHigh+innovation+%2b+low+cost+IP+Know-how%0d%0a%0d%0aMarket+Bridging+the+gap%e2%80%a6.%0d%0a%0d%0aAcademia%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhat+is+Technology+Transfer%3f%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhat+do+you+need%3f%0d%0a%0d%0a(14)%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0aCreative+researchers+Ideas+with+commercial+applications+Clearly+definable+Development+pathway+Protection+of+Investment+%2f+monopoly+%e2%80%93+Patent+or+proprietary+K%2fH+Good+communication+skills+The+vision+to+see+the+potential+and+Process+to+log+inventions+disclosures+The+patience+to+follow+a+lengthy+process+A+positive+attitude+of+investigators%2finventors+towards+industry+and+the+correct+culture+within+the+institute+(rewards+for+inventors+schemes+%2f+TTO)+Money+to+finance+TTO+and+patent+applications+Pro-active+marketing+skills+Legal+expertise+Patent+expertise+Broad+scientific+knowledge+Broad+commercial+knowledge%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aSubstantive+requirement+for+patents+A+reminder!%0d%0a%0d%0a%e2%80%a2+Novel+-+not+disclosed+prior+to+filing+in+any+way+(including+internet%2c+and+oral+presentations%2c+demonstrations+or+oral+descriptions+made+without+correct+confidentiality+agreements)%0d%0a%0d%0a%e2%80%a2+Inventive+Step+-+surprising%2c+not+an+obvious+development+from+what+is+already+known+in+the+prior+art%0d%0a%0d%0a%e2%80%a2+Industrial+Application%2fUtility%2c+containing+an+enabling+disclosure%0d%0a%0d%0a%e2%80%a2+Relevance+to+genome%2fgene+related+patents+%e2%80%93+support%2fsufficiency%2finventive+step%2futility%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aR+%26+D+%e2%80%93+Time+and+Cost%0d%0a%0d%0aEarly-stage+Research+and+discovery%0d%0a%0d%0aPreclinical+studies%0d%0a%0d%0aPhase+I%0d%0a%0d%0aPhase+II%0d%0a%0d%0aPhase+III%0d%0a%0d%0aRegulatory+Review%2f+Approval%0d%0a%0d%0aPhase+IV%0d%0a%0d%0a%3f+years%0d%0a%0d%0a1-2+years%0d%0a%0d%0a1-2+years%0d%0a%0d%0a1-2+years%0d%0a%0d%0a2-3+years%0d%0a%0d%0a1-2+years%0d%0a%0d%0a5000%0d%0a%0d%0a250%0d%0a%0d%0a5%0d%0a%0d%0a1%0d%0a%0d%0aNo.+of+compounds+advanced+at+each+stage%0d%0a%0d%0aCOST+%24500M-%24800M+(%c2%a31.7billion!)%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aPharma+Innovation+Gap%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aReasons+for+Termination%0d%0a%0d%0aTufts+Center+for+the+Study+of+Drug+Development%3a+Outlook+2005%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aSuccess+Rates+source+Nature+Reviews+Drug+Discovery%0d%0aAug+2004%0d%0a%0d%0aPercent+Success+Rates+from+first+in+man+to+registration%0d%0a20+18+16+14+12+percent+10+8+6+4+2+0%0d%0a%0d%0aArthritis%2fPain+Cardiovascular+CNS%0d%0a%0d%0aInfectious+Oncology+Opthalmology+Metabolic+Disease+Disease%0d%0a%0d%0aUrology%0d%0a%0d%0aWomen's+Health%0d%0a%0d%0aAll%0d%0a%0d%0aindication%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aAcademia%2fIndustry+Partnership%0d%0aPharma%2fBiotech+industry+to+deliver+their+mission.%0d%0a%0d%0a(4)%0d%0a%0d%0a%e2%80%a2+Charities+and+other+%e2%80%9cacademic%e2%80%9d+Institutions+need+to+engage+with%0d%0a%0d%0a%e2%80%a2+Industry+hunger+for+new+%e2%80%9cinventions%e2%80%9d+(in+licensed+drugs+vs+in+house)+%e2%80%a2More+drug+withdrawals+(Vioxx+%2f+Iressa+%2f+Baycol)+and+blockbusters+going+off+patent+(Zantac%2faugmentin%2fprozac%2fNorvasc)+BUT+%e2%80%a2+%e2%80%9cInventions%e2%80%9d+with+an+appropriate+risk%2freward+balance%3a+%e2%80%a2+Supported+by+rights+to+commercial+monopoly+%e2%80%93+strong+Patents%0d%0a%0d%0a%e2%80%a2+More+advanced+projects+favoured%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhat+Models+can+be+Adopted+%3f%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aTechnology+transfer+models%3a+Strategic+Parameters%0d%0a%0d%0aSize%0d%0a%0d%0aEnvironment%0d%0a%0d%0aMission%0d%0a%0d%0aIP+Ownership%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aTechnology+transfer+models%3a+Influencing+factors%0d%0a%0d%0a%ef%83%98+Who+owns+the+TTO%3f%0d%0a%ef%83%98+What+is+the+legal+and+Organisational+relationship+of+the+TTO+with+the+funding+body+%2f+institute%3f+%ef%83%98+How+is+the+Operation+structured%3f%0d%0a%0d%0a%ef%83%98+How+are+the+Functions+within+the+TTO+managed%3f%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWho+owns+the+TTO%3f%3a+University%0d%0a%0d%0aUniversity%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Diverse+and+rich+source+of+IP+and+know-how%0d%0a%0d%0a%e2%80%a2+Usually+on-site+office%0d%0a%0d%0aDiverse+disciplines%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Difficult+for+TTO+to+develop+technical+expertise+in+diverse+disciplines%0d%0a%e2%80%a2+TTO+require+lots+of+resource+in+order+to+effectively+interact+with+all+the+individual+departments%0d%0a%0d%0aTTO%0d%0a%0d%0a%e2%80%a2+More+difficult+for+TTO+to+build+long-term+relationship+with+diverse+industries%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWho+owns+the+TTO%3f%3a+Research+Council%0d%0a%0d%0aResearch+council%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Individual+research+institutes+tend+to+have+a+degree+of+focus+e.g.+engineering+vs.+medicine+%e2%80%a2+TTO+can+have+%e2%80%9erelationship+managers%e2%80%9f+to+interface+with+individual+research+institutes%0d%0a%0d%0aSingle+discipline%0d%0a%0d%0a%e2%80%a2+Potential+to+centralise+certain+functions%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+IP+often+pre-competitive+%e2%80%a2+Off-site+office+away+from+labs%0d%0a%0d%0aTTO%0d%0a%0d%0a%e2%80%a2+IP+ownership+issues%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWho+owns+the+TTO%3f%3a+Charity+%2f+Consortia%0d%0a%0d%0aCharity%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Charity+and+TTO+likely+to+share+the+same+mission+of+patient+benefit+%e2%80%a2+Very+focussed+-+helps+TTO+to+build+requisite+technical+expertise+and+contacts+in+the+industry%0d%0a%0d%0aSingle+discipline%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Difficult+to+exploit+opportunities+outside+of+focus+area+%e2%80%a2+IP+ownership+issues%0d%0a%0d%0aTTO%0d%0a%0d%0a%e2%80%a2Offsite+office%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWho+owns+the+TTO%3f%0d%0a%0d%0aDecreasing+Complexity%0d%0a%0d%0aCharity%0d%0a%0d%0aResearch+Council%0d%0a%0d%0aUniversity%0d%0a%0d%0aIncreasing+Focus%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOrganisation%3a+Fully+integrated%0d%0a%0d%0aPros%3a%0d%0aCommercialisation+%e2%80%a2+Greater+interaction+between+TTO+and+Host+institution+scientists+%e2%80%a2+Alignment+with+policies%2fcharters+of+Host+institution%0d%0a%0d%0aTechnology+expertise%0d%0a%0d%0aHost+Institute%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Tax+issues+%e2%80%a2+Increased+liability+%e2%80%a2+Increased+bureaucracy%0d%0a%0d%0aIP+management%0d%0a%0d%0aDepartment+of+the+Host+Institution%0d%0a%0d%0a%e2%80%a2+Lack+of+autonomy+can+lead+to+less+opportunity+to+offer+bespoke+career+structure%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOrganisation%3a+Separate+company%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Favourable+tax+structure+Commercialisation%0d%0a%0d%0a%e2%80%a2+Host+institution+sheltered+from+liability+issues%0d%0a%e2%80%a2+Speed+of+movement%0d%0a%0d%0aTechnology+expertise%0d%0a%0d%0a%e2%80%a2+Ability+to+offer+more+attractive+career+structure+%e2%80%a2+Companies+like+interacting+with+Companies!%0d%0a%0d%0aIP+management%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Potential+for+decreased+interaction+between+Host+institution+and+TTO+%e2%80%a2+Potential+for+less+alignment+with+policies%2fcharter+of+Host+institution%0d%0a%0d%0aSeparate+company+owned+by+the+Host+Institution%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOrganisation%3a+Hybrid%0d%0a%0d%0aPros%3a%0d%0aCommercialisation%0d%0a%e2%80%a2+Favourable+tax+structure+%e2%80%a2+Host+institution+sheltered+from+liability+issues+Technology+expertise+%e2%80%a2+Greater+interaction+between+TTO+and+Host+institution%0d%0a%0d%0aShell+company%0d%0a%0d%0aSeparate+company+IP+owned+by+the+management+Host+Institution+in+which+IP+is+vested+and+Department+of+revenues+the+Host+Institution+received%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Increased+bureaucracy+%e2%80%a2+Inability+to+offer+attractive+career+structure+%e2%80%a2+Extended+IP+Chain%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOperation%3a+Centralised%0d%0a%0d%0aPros%3a%0d%0aCommercialisation+%e2%80%a2+Greater+interaction+between+all+functions+of+the+TTO%0d%0a%e2%80%a2+Easier+to+implement+a+uniform+IP+management+policy+across+the+institution%0d%0a%0d%0aTechnology+expertise%0d%0a%0d%0aCons%3a%0d%0aIP+management+%e2%80%a2+More+difficult+for+TTO+to+be+in+regular+and+close+contact+with+scientists+in+different+departments%0d%0a%0d%0aCentral%0d%0a%0d%0aE.g..+CRT%2c+Max+Planck%2c+NIH%2c+MRC%2c+Fraunhoffer%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOperation%3a+Distributed%0d%0a%0d%0aTechnology+%26+Commercialisation+Expertise+Technology+%26+Commercialisation+Expertise%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Easier+for+TTO+to+be+in+regular+contact+with+scientists%0d%0a%0d%0aDepartment+IP+management%0d%0aCentral%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2More+difficult+to+implementing+a+uniform+IP+policy+across+the+institution%0d%0a%0d%0aE.g.+Nottingham+University+and+some+Research+Councils%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aOperation%3a+External%0d%0a%0d%0aCentral%0d%0a%0d%0aPros%3a%0d%0aCommercialisation+Host+Institute%0d%0a%e2%80%a2+Access+to+greater+resource%2c+technology+expertise+and+market+knowledge+%e2%80%a2+Allows+smaller+offices+to+effectively+commercialise+technologies%0d%0a%0d%0aTechnology+expertise%0d%0a%0d%0aCons%3a%0d%0aIP+management+External+Company%2fAgency+%e2%80%a2+Loss+of+control+%e2%80%a2+Lesser+possibility+to+build+skills+in-house%0d%0a%0d%0aE.g.+Technologie+Lizenz+Buro+in+Germany+VIB+in+Belgium%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aFunction%3a+Cradle+to+Grave%0d%0a%0d%0aProject+Identification%0d%0a%0d%0aPatent+Filing%0d%0a%0d%0aProject+Development%0d%0a%0d%0aLicence+Post-Signature+Marketing+Collaboration+Management+Spin-out%0d%0a%0d%0aPros%3a%0d%0a%e2%80%a2+Works+for+any+size+of+office+%e2%80%a2+Single+%e2%80%9eContact%e2%80%9f+point+for+Inventors+and+Companies+%e2%80%a2+Better+alignment+of+scientific+and+Commercial+due-diligence+%e2%80%a2+Ability+to+offer+better+career+development+opportunities+%e2%80%a2+Personnel+motivation%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0aCons%3a%0d%0a%e2%80%a2+Requires+experienced+professionals+%e2%80%a2+Lengthy+training+period+%e2%80%a2+Less+opportunity+to+specialise%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aFunction%3a+Specialised%0d%0a%0d%0aProject+Identification%0d%0a%0d%0aPatent+Filing+Project+Development%0d%0a%0d%0aMarketing%0d%0a%0d%0aPost-Signature+Management+Licence+Collaboration+Spin-out%0d%0a%0d%0aCons%3a+Pros%3a%0d%0a%e2%80%a2+Easier+to+recruit+%e2%80%a2+Shorter+training+period+%e2%80%a2+Opportunity+to+specialise+%e2%80%a2+Less+suitable+for+small+office+%e2%80%a2+Less+scope+to+reap+the+reward+of+one%e2%80%9fs+handwork+%e2%80%a2+Less+scope+for+alignment+of+scientific+and+commercial+due-diligence%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aFocused+Technology+Transfer+Company+Model%3a+CRT%0d%0aOrganisation%0d%0aSeparate+Company%0d%0aCommercialisation+Technology+expertise+IP+management%0d%0a%0d%0aOwner%0d%0aCharity+Cancer+Research+UK%0d%0a%0d%0aOperation%0d%0aCentralised+Commercialisation+Technology+expertise+IP+management%0d%0a%0d%0aOncology%0d%0a%0d%0aFunction%0d%0aCradle+to+Grave%0d%0a%0d%0aCRT%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCommercialisation+routes%0d%0a%0d%0a(14)%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a1.%0d%0a%ef%83%98%0d%0a%0d%0aLicensing+(vs+assignment+which+is+not+recommended)%0d%0aWhat+is+the+reason+-+-freedom+to+operate+vs+monopoly+required+for+investment+return%3f+collaboration+with+time+limited+rights%3f+Is+an+exclusive+Option+a+better+mechanism%3f+How+confident+are+you+in+the+partners+ability+to+develop+and+market%3f+How+likely+is+a+sub-licensing+event%3f+Development+plans+scheduled+with+time+lines+Termination+rights+%e2%80%93+under+what+eventualities+How+have+you+calculated+financial+considerations%3f+Who+pays+for+and+manages+the+patents%3f+Have+you+included+improvements+(institute+wide+or+for+the+inventor%e2%80%9fs+lab%3f)+Patents+filed+(how+old%3f+How+costly%3f)+Know-how+%2f+Materials+Exclusive+%e2%80%a2+Grant+to+all+fields+or+restricted+fields+%e2%80%a2+Grants+to+all+territories+or+selection+Non-Exclusive+Liabilities+and+Warrantees%0d%0a%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0a2.%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0aStart-ups+%2f+Spin+%e2%80%93out+companies%0d%0a%0d%0aCommercialisation+routes%0d%0a%0d%0a(18)%0d%0a%0d%0a%ef%83%98%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aNow+in+post-March+2000+reality+check+Have+you+got+a+deep+and+wide+enough+patent+portfolio+(and+pockets)+Have+you+got+a+large+enough+potential+market+Are+you+a+one+product+%e2%80%93+one+hit+wonder+(nightmare)+Are+development+plans+realistic+How+far+can+you+develop+this+in-house+first%3f+Do+you+use+seed+funding+%2f+incubators+first+What+type+of+investment+(how+far+away+are+revenues%3f)+%e2%80%93+mostly+VC%e2%80%9fs+or+Angels+How+committed+are+the+founders%3f+Will+the+founders+maintain+their+position+at+the+Institute%3f+How+much+equity+will+the+institute%2c+inventors%2c+founders+receive%3f+Who+will+write+the+business+plan+and+market+it+around+investors%3f+Who+will+draft+all+the+legal+documents%3f+When+do+you+second+a+CEO+%2f+lawyer+%2fmanagement+Where+will+you+base+your+company%3f+What+are+the+risks%3f+How+have+you+planned+for+them%3f+Can+you+prepare+a+parachute+for+the+IP+to+be+retrieved+if+the+company+idea+fails+%e2%80%93+assignment+vs+licenses+Will+you+want+royalties+as+well+as+equity+Does+the+company+need+a+pipeline+to+institute+IP%3f%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCommercialisation+routes%0d%0a%0d%0a(9)%0d%0a%0d%0a%e2%80%a2+3.%0d%0a%ef%83%98%0d%0a%0d%0aCollaborations%0d%0aCapitalise+on+reputations+and+expertise+Don%e2%80%9ft+necessarily+need+a+patent+application+Build+on+mutual+input+and+reward+(not+just+financial)+Not+contract+research!+Maintain+academic+freedom+and+publication+rights+Often+are+the+basis+for+an+ensuing+licence+with+an+option+built+in+to+the+collaboration+Provide+extra+researchers+and+equipment+to+academic+laboratory+Provide+access+to+industry+strengths+in+compounds+%2f+screening+%2f+bioinformatics+%2f+imaging+%2f+databases+and+other+expensive+platforms+Beware+of+industrial+sponsorships+and+MTA%e2%80%9fs+for+proprietary+compounds+being+called+collaborations+but+demanding+full+ownership+of+all+IP+in+a+field+not+just+that+arising+from+the+sponsored+researchers!%0d%0a%0d%0a%ef%83%98%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aIndustry+Trends%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhat+does+a+licensee+look+for+in+a+biotech+type+opportunity+now+%3f+(10)%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0aHigh+quality+proof+of+principle.+A+publication+in+a+high+impact+journal+is+not+the+whole+story.+In+vivo+experiments+normally+Strong+patent+position+(target%2fscreening+patents+have+debatable+value+but+may+give+an+edge+over+Competitive+groups+%2f+priority+date)+Cellular+validation+a+minimum+RNAi+or+(research+grade)+small+molecule+inhibitor+to+validate+targets+Presence+of+target+correlated+to+disease+in+tumour+vs+normal+Broad+validation+of+a+platform+technology+Endorsement%2fpeer+review+of+leaders+in+the+field+Track+record+of+researchers+in+dealing+with+industry+Names+with+international+repute%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aBiotech+Deal+Trends%0d%0a%0d%0a(10)%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0aMore+pharma+in+licence+now+than+ever+before+(still+mostly+from+biotech+or+other+pharma+in+financial+terms)%0d%0a%ef%83%98%0d%0a%0d%0aBetween+2001%2f02+top+20+pharma+in+licensed+deals+increased+by+23%25(Booz%2fAllen%2fHamilton%3a2003)%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0a%e2%80%a2%0d%0a%e2%80%a2%0d%0a%0d%0aPharma+less+likely+to+take+early+pre-clinical%2ftarget+based+licences+Much+higher+financial+terms+for+phase+III+but+also+phase+I+and+II+agents+(BMS%2fImclone%3bAventis%2fGenta)+Acquisitions+and+mergers+prevalent+Blockbusters+have+to+be+%3e%241billion+annual+sales.+Pharma+needs+between+2-9+launched+per+annum+depending+on+size+of+company+to+maintain+size+More+biotechs+are+picking+up+the+lower+%c2%a350+-+%c2%a3250m+sized+drugs+and+orphan+drug+status+in+USA+and+Europe+is+helping+this.+Pharmacogenomics%2fpersonalised+medicine+and+prognostic+markers+are+beginning+to+have+an+impact+on+drug+development+and+administration+(Her2neu%2fHerceptin%3b+Iressa%2fEGFR%3b+)+Start-ups+become+fewer+in+number+but+get+higher+first+round+funding+to+survive+longer+before+raising+more+money+Europe+consolidating+industry%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aNo+of+in-licensed+programmes%0d%0a%0d%0ano+of+in-licensed+deals+by+dev+stage%0d%0a30%0d%0a%0d%0ano+of+inlicensed+compounds%2fagents%0d%0a%0d%0a25+20+15+10+5+0+preclin+phase+I+Phase+II+Phase+III+dev+stage%0d%0a%0d%0a1997%2f8+1999%2f2000+2001%2f2%0d%0a%0d%0aSource+Scrip+magazine+(Recap%2c+Pharmaprojects+%26+Windover)%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aWhy+Should+you+worry+about+talking+to+a+technology+transfer+professional%3f%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0aThey+cant+start+working+for+you+until+they+know+what+you+want!+They+can+guide+you+on+how+to+protect+your+research+without+changing+timelines+to+publications+They+can+advise+on+what+is+patentable+They+can+tell+you+if+your+competitors+have+patents+out+in+your+field+They+can+find+industrial+collaborators+for+you+They+can+organise+the+patent+filing+They+can+negotiate+terms+for+the+best+return+on+your+invention+and+find+the+most+suitable+commercialisation+partner+They+can+find+a+distributor+for+your+reagents+They+can+make+sure+no+US+based+collaborator+walks+away+with+rights+to+your+research+through+in-bound+MTA%e2%80%9fs+They+can+protect+you+personally+and+the+institute+from+liabilities+and+future+law+suits+arising+from+signing+agreements+They+can+increase+your+profile+within+the+organisation+They+can+set+you+on+your+way+to+being+the+next+biotech+entrepreneur+(if+that%e2%80%9fs+what+you+want)+They+can+often+advise+you+on+means+to+obtain+translational+funding+IF+IN+DOUBT+ALWAYS+GIVE+THEM+A+SHOUT!!%0d%0a%0d%0aPlease+talk+to+Tech+Transfer+Professionals+-Why%3f+(14)%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aThe+CRT+Story%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+%26+Cancer+Research+UK%0d%0a%0d%0a%e2%80%a2+CRT+is+wholly+owned+by+Cancer+Research+UK+%e2%80%a2+Cancer+Research+UK+is+the+world's+largest+charity+dedicated+to+research+on+the+causes%2c+treatment+and+prevention+of+cancer+%e2%80%a2+The+charity+funds+over+3000+scientists%2c+doctors+and+nurses+based+throughout+the+UK%0d%0a%0d%0a%e2%80%a2+Annual+research+spend+in+excess+of+%c2%a3213m%0d%0a%e2%80%a2+Cancer+Research+UK+is+a+European+leader+in+the+development+of+anti-cancer+drugs.+Over+90+new+anti-cancer+agents+taken+into+clinical+trials+since+1980%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aVision+%26+Uniqueness%0d%0a%0d%0aVision%3a+%e2%80%a2+To+maximise+cancer+patient+benefit+from+publicly+funded+cancer+research.+%e2%80%a2+To+maximise+revenues+for+investment+in+further+cancer+research+%e2%80%a2+To+be+recognised+as+the+leading+oncology-focused+technology+transfer+and+development+company%0d%0a%0d%0aUniqueness+%e2%80%a2+Oncology+Focused+%e2%80%a2+Third+Party+Partnerships%0d%0a%0d%0a%e2%80%a2+Drug+discovery%2c+preclinical+and+clinical+development+resources+and+capability%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCompany+Structure%0d%0aHarpal+Kumar+CEO+CRT%2c+COO+Cancer+Research+UK+Keith+Blundy+Chief+Operating+Officer+Finance+Team%0d%0a%0d%0aMarketing+Team%0d%0a%0d%0aPatents+%26+Legal+Team%0d%0a%0d%0aDr+Phil+L%e2%80%99Houllier%2c+Director+of+Business+Management%0d%0a%0d%0aClive+Stanway%2c+Director+of+Technology+Development+Medicinal+Chemistry+Cell+Biology%0d%0a%0d%0aBusiness+Manager+Teams+(x5)%0d%0a%0d%0aDiagnostic+%26+Research+Tools%0d%0a%0d%0aDrug+Discovery+Molecular+Biology%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCompany+Information%0d%0a%0d%0a%e2%80%a2+Over+17+years+in+oncology-focused+technology+transfer+%e2%80%a2+Over+65+employees+%e2%80%a2+Currently+managing+over+200+projects%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0a%3e30+licensing%2fcollaboration+deals+per+annum+15+partnered+early+and+late+stage+clinical+development+projects%0d%0a%0d%0a%e2%80%a2+3+partnered+cancer+therapeutics+on+the+market+%e2%80%a2+18+spin+out+companies+%e2%80%a2+Total+revenue+of+%7e+%c2%a320m+pa+(c28m+Euros)%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aTechnology+Transfer+Benchmarks%0d%0aResearch+expenditure+License+income+as+a+percentage+of+research+expenditure+Research+Expenditure+%2f+Licenses+yielding+income+New+patents+filed+U.S.+patents+issued+New+start-ups%0d%0a%0d%0aInstitution%0d%0a%0d%0aLicense+income%0d%0a%0d%0aFlorida+State+University+Columbia+University+University+of+California+System%0d%0a%0d%0a%2467%2c497%2c034+%24138%2c562%2c416+%24261%2c522%2c000%0d%0a%0d%0a%24136%2c284%2c150+%24311%2c121%2c727+%242%2c084%2c623%2c000%0d%0a%0d%0a49.5%25+44.5%25+12.5%25%0d%0a%0d%0a%2411%2c357%2c013+%242%2c175%2c676+%242%2c669%2c172%0d%0a%0d%0a33+96+432%0d%0a%0d%0a16+78+324%0d%0a%0d%0a2+7+26%0d%0a%0d%0aCRT+*%0d%0aStanford+University+University+of+Pennsylvania+University+of+Washington+MIT+Harvard+UK+Universities+average%0d%0a%0d%0a%2426%2c191%2c315%0d%0a%2434%2c603%2c000+%2426%2c493%2c392+%2430%2c212%2c714+%2430%2c234%2c664+%2412%2c194.919+%24497%2c178%0d%0a%0d%0a%24331%2c700%2c000%0d%0a%24444%2c274%2c655+%24529%2c554%2c951+%24652%2c100%2c000+%24727%2c600%2c000+%24430%2c780%2c600+Not+available%0d%0a%0d%0a7.9%25%0d%0a7.8%25+5.0%25+4.6%25+4.2%25+2.8%25+-Source%3a%0d%0a%0d%0a%246%2c258%2c490%0d%0a%241%2c175%2c330+%2411%2c767%2c888+%241%2c693%2c766+%242%2c009%2c945+%242%2c642%2c826+Not+available%0d%0a%0d%0a12%0d%0a162+84+72+180+64+11%0d%0a%0d%0a11%0d%0a98+50+59+152+56+8%0d%0a%0d%0a1%0d%0a8+6+6+31+1+2%0d%0a%0d%0a*CRT+data%3a+FY+2003-2004+%c2%a3+to+%24+exchange+rate%3a+1.80%0d%0a%0d%0aUS+University+data%3a+MIT%e2%80%99s+Magazine+of+Innovation%2c+Tech+Transfer+Riches+2002+UK+University+data%3a+UNICO+2003-04+Survey%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+Partnered+Marketed+Therapeutics%3a%0d%0a%0d%0aTemodar%2fTemodal%2fTemozolomide+(Schering+Plough)+%e2%80%a2+Launched+in+September+1999+%e2%80%a2+First+New+Chemotherapy+Agent+for+Brain+Tumours+in+20+Years+%e2%80%a2+Oral+alkylating+agent+Tomudex+(AstraZeneca)+%e2%80%a2+Injectable+cytotoxic+agent+(TS+inhibitor)+for+advanced+colorectal+cancer+Zinecard+(Pfizer)+%e2%80%a2+Cardioprotective+agent+used+during+chemotherapy+with+doxorubicin%3b+Patent+expired%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aPartnered+Therapeutics%0d%0a%0d%0aSelected+Partnered+Therapeutics+in+Clinical+Trials%0d%0aSatraplatin+BLP25+VV-MUC1-IL2+Small+Molecule+ICR+Guy%e2%80%9fs+Hospital+Newcastle+Nottingham+ICR+GPC+%26+Spectrum+Biomira+Transgene%0d%0a%0d%0aPeptide+Vaccine+Guy%e2%80%9fs+Hospital+DNA+Vaccine%0d%0a%0d%0aPARP+Inhibitors+Small+Molecule%0d%0aPhortress+NX473+Patrin2+DMXAA+105AD7+5T4+Small+Molecule+Small+Molecule+Small+Molecule+Small+Molecule+Antibody+Antibody%0d%0a%0d%0aAgouron%2fPfizer%0d%0aPharminox+NeoRx%0d%0a%0d%0aTrinity+IRL+and+PICR+KuDOS+Pharmaceuticals+Auckland%2c+NZ+Nottingham+PICR+Antisoma+Onyvax+Oxford+BioMedica%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aPartnered+Therapeutics%0d%0a%0d%0aSelected+Partnered+Therapeutics+in+Pre-clinical+Development%0d%0aHSP90+Small+Molecule+ICR+Vernalis%2fNovartis%0d%0a%0d%0aRNAi%0d%0aATM+Inhibitors+DNA-PK+Inhibitors+B-RAF+Inhibitors%0d%0a%0d%0aBiological%0d%0aSmall+Molecule+Small+Molecule+Small+Molecule%0d%0a%0d%0aCambridge%2fNKI%0d%0aNewcastle+Newcastle+ICR%0d%0a%0d%0aAlnylam%0d%0aKuDOS+KuDOS+Astex%0d%0a%0d%0aOncology+Target%0d%0aQuinols+Telomerase+Inhibitors+CD55+Quinazolines%0d%0a%0d%0aBiological%0d%0aSmall+Molecule+Small+Molecule+Vaccine+Small+Molecule%0d%0a%0d%0aOxford%0d%0aNottingham+ICR+Nottingham+ICR%0d%0a%0d%0aGenentech%0d%0aPharminox+Antisoma+Scancell+BTG%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aStart-up+Companies%0d%0aCRT+Followed+%e2%80%a2+Antisoma%0d%0a%0d%0aCRT+Led+%e2%80%a2+Chroma+Therapeutics+%e2%80%a2+Crusade+Laboratories+%e2%80%a2+Cyclacel+%e2%80%a2+InferMed+%e2%80%a2+KuDOS+Pharmaceuticals%0d%0a%0d%0a%e2%80%a2+Epistem%0d%0a%e2%80%a2+Hybrid+Systems+%e2%80%a2+PETTRA%0d%0a%0d%0a%e2%80%a2+Phogen%0d%0a%e2%80%a2+Phototherapeutics+%e2%80%a2+PIramed+%e2%80%a2+Spirogen+%e2%80%a2+Congenia+%e2%80%a2Immpact%0d%0a%0d%0a%e2%80%a2+Spear%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aExamples+in+Practice+%e2%80%93+CRT%e2%80%99s+current+clinical+portfolio%0d%0aLymphoma%2c+1+Cervical%2c+1%0d%0a%0d%0aCancer+type%0d%0a%0d%0aMelanoma%2c+1+Gastric%2c+1+Ovarian%2c+2%0d%0a%0d%0aProstate%2c+5%0d%0a%0d%0aRenal%2c+2%0d%0a%0d%0aLung%2c+4%0d%0a%0d%0aColorectal%2c+4+Breast%2c+5%0d%0a%0d%0aNote%3a+Excludes+a+further+7+in+early+Phase+I+for+Solid+tumours%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+Clinical+pipeline%3a+Licensed%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+Clinical+pipeline%3a+Licensed%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aDevelopment+Capabilities%0d%0a%0d%0aDrug+Discovery%2c+Preclinical+and+Clinical+Development+Capabilities%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+Development+Laboratory%0d%0a%0d%0a%e2%80%a2+In-house+resource+to+increase+the+number+of+discoveries+developed+into+true+therapeutic%2fdiagnostic+opportunities+%e2%80%a2+Capable+of+taking+projects+to+proof+of+efficacy+stage+in+vivo%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0aTarget+validation+Lead+compound+generation+Development+of+biological+therapeutics+and+diagnostics+Reagents+and+data+returned+to+originating+lab%0d%0a%0d%0a%e2%80%a2+36+Research+personnel.+%e2%80%a2+Currently+conducting+9+small+molecule+and+4+biological+drug+development+programmes%0d%0a%0d%0a%e2%80%a2+Service+offered+to+cancer+research+community%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCRT+Development+Laboratory%0d%0aTarget%0d%0aDrug+Discovery%0d%0aLibrary+management%2c+Protein+production+Assay+development%2c+Screening%2c+Hit+profiling%0d%0a%0d%0aMolecular+Biology%0d%0aCloning%2c+mAb+production%2c+Protein+expression%2c+Gene+analysis%0d%0a%0d%0aCell+studies%2c+Angiogenesis%2c+Invasion%2c+Microscopy%2c+siRNA+studies%2c+Animal+model+work%2c+ADME+-TOX%0d%0a%0d%0aCompound+synthesis+H2L%2c+lead+optimisation+Library+QC+and+expansion+In+Silico+analysis%0d%0a%0d%0aCell+Biology%0d%0a%0d%0aBiological+Therapies+or+Drug-Like+Compounds%0d%0a%0d%0aMedicinal+Chemistry%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aDrug+Development+Office%0d%0a%0d%0a%e2%80%a2+Cancer+Research+UK+Drug+Development+Office+track+record+in+Phase+I+trials+on+novel+therapeutics%3a%0d%0a%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0a90+new+compounds+into+man+over+past+20+years+Small+molecules%2c+antibodies%2c+gene+therapy%2c+vaccines%2c+etc.+10+new+trials+per+annum+Access+to+GMP+facilities+for+small+molecules+and+biotherapeutics+GCP+trial+compliance%0d%0a%0d%0a%e2%80%a2+Through+CRT%2c+partners+can+access+drug+development+capabilities+and+add+value+to+projects+by+conducting+trials+with+Cancer+Research+UK%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aPartnerships%0d%0a%0d%0aPartnership+in+delivering+patient+benefit%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aAcademic+Partners+(UK)%0d%0a%0d%0a%e2%80%a2+Cancer+Research+UK%0d%0a%0d%0a%e2%80%a2+Other+UK+Charities+under+an+umbrella+agreement%3a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aLeukaemia+Research+Fund+Kay+Kendall+Leukaemia+Fund%0d%0a%0d%0a%ef%83%98%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aBreast+Cancer+Campaign%0d%0aMarie+Curie+Cancer+Care+Association+for+International+Cancer+Research%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aInternational+Academic+Partners%0d%0aUmbrella+Agreement%0d%0a%0d%0a%e2%80%a2+Netherlands+Cancer+Institute+%e2%80%a2+European+Institute+of+Oncology%2c+Italy+%e2%80%a2+Danish+Cancer+Society+Project+by+project+basis+%e2%80%a2+Deutches+Krebsforschungszentrum%2c+Germany+%e2%80%a2+Consejo+Superior+de+Investigaciones+Cientificas%2c+Spain+%e2%80%a2+Karolinska+Institute%2c+Sweden+-+solely+commercialisation%0d%0a%0d%0a%e2%80%a2+Auckland+Division+Cancer+Society+of+New+Zealand%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aBenefits+of+working+with+CRT%0d%0a%0d%0a%e2%80%a2%0d%0a%0d%0aCancer+Focused+%e2%80%93+Extensive+expertise+and+considerable+experience+can+be+brought+to+bear+on+evaluating%2c+protecting%2c+developing+and+commercialising+oncology+related+inventions.+Partnerships+in+IP+management+-+Extensive+track+record+in+well+managed+and+productive+relationships+with+3rd+party+academic+partners.+Flexible+working+and+financial+arrangements+to+complement+the+needs+of+our+research+partners.+Development+funding+%e2%80%93+Potential+for+access+to+funding+for+development+of+early+stage+inventions+into+commercially+attractive+opportunities+CRT+Development+Laboratory+%e2%80%93+Potential+for+access+to+the+CRT+DL+resources.%0d%0a%0d%0a%e2%80%a2+%e2%80%a2+%e2%80%a2+%e2%80%a2%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aThank+You%0d%0a%0d%0aCancer+Research+Technology%0d%0aExploiting+Research+for+the+Benefit+of+Cancer+Patients%0d%0a%0d%0awww.cancertechnology.co.uk%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Studies%0d%0a%0d%0a%e2%80%a2+University+of+Cambridge+and+the+the+Netherlands+Cancer+Institute+(NKI)%0d%0a%ef%83%98%0d%0a%0d%0aPlatform+technology+(RNAi+and+pSUPER+vector+system)+licensed+for+multiple+applications%0d%0a%0d%0a%e2%80%a2+Institute+of+Cancer+Research+and+RiboTargets+(now+Vernalis)%0d%0a%ef%83%98%0d%0a%0d%0aHSP90+research+collaboration%0d%0a%0d%0a%e2%80%a2+University+of+Cambridge%0d%0a%ef%83%98%0d%0a%0d%0aKuDOS+Pharmaceuticals+-+start+up+company%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+RNAi%0d%0a%0d%0a%e2%80%a2+The+Technology%0d%0a%ef%83%98%0d%0a%0d%0aNew+method+of+selective+gene+silencing+using+dsRNA%0d%0a%0d%0a%e2%80%a2+CRT%e2%80%9fs+patent+portfolio%0d%0a%ef%83%98%0d%0a%0d%0aUniversity+of+Cambridge+(Prof.+David+Glover)+patent+covering+the+use+of+dsRNA+in+mammalian+cells+Netherlands+Cancer+Institute+(Prof.+Rene+Bernards)+pSUPER+patent+covers+a+vector+designed+to+express+the+optimal+RNAi+effector+as+a+short+hairpin+By+virtue+of+an+umbrella+agreement+with+each+institute+CRT+owns+these+patents%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+RNAi%0d%0a%0d%0a%e2%80%a2+Target+validation+%e2%80%93+RNAi+to+validate+individual+genes+as+disease+targets%3a%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aGlover+and+Bernards+package+marketed+3+non-exclusive+licenses+to+date%0d%0a%0d%0a%e2%80%a2+RNAi+library+%e2%80%93+Cancer-focused+against+8000+human+genes%3a%0d%0a%ef%83%98%0d%0a%0d%0aCollaboration+between+researchers+at+NKI+and+Cancer+Research+UK%0d%0a%0d%0a%e2%80%a2+Therapeutics+%e2%80%93+selective+knockdown+of+disease-related+genes%3a%0d%0a%ef%83%98%0d%0a%0d%0aExclusive+licence+to+Alnylam+Pharmaceuticals%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+HSP90%0d%0a%0d%0a%e2%80%a2+The+Technology%0d%0a%ef%83%98%0d%0a%0d%0aHSP90+is+a+molecular+chaperone+cancer+target+that+was+the+focus+of+a+screening+programme+at+the+Institute+of+Cancer+Research+by+Prof.+Paul+Workman%0d%0a%0d%0a%e2%80%a2+Research+collaboration+initiated+with+Vernalis%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0aTo+identify+and+develop+HSP90+inhibitors+as+cancer+therapeutics+The+Institute+provide+%e2%80%9ewet%e2%80%9f+screening%2c+secondary+assays%2c+chemistry%2c+PK%2fPD+analysis+and+in+vivo+work+Vernalis+provide+in+silico+screening%2c+chemistry+and+drug+development+capability+By+virtue+of+an+umbrella+agreement+with+the+Institute+CRT+owned+the+original+intellectual+property+in+this+area+and+negotiated+the+agreement%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+HSP90%0d%0a%0d%0a%e2%80%a2+CRT+filed+a+patent+on+the+assay+and+a+%e2%80%9ehit%e2%80%9f+and+took+assignment+%e2%80%a2+Commercial+decision+taken+to+keep+the+project+in-house%0d%0a%ef%83%98%0d%0a%0d%0aSeed+Fund+award+for+3+employees+for+2+years+to+work+up+the+chemistry+on+the+HSP90+hit+and+to+identify+a+lead+candidate%0d%0a%0d%0a%e2%80%a2+Approached+by+Vernalis+who+had+a+complimentary+approach+%e2%80%a2+CRT+negotiated+and+drafted+a+collaboration+and+option+agreement+(with+scheduled+licence+agreement+for+option+exercise)%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aResearch+funded+for+2-3+years+to+identify+a+clinical+candidate+Signature+fee%2c+development+milestones+and+royalty%0d%0a%0d%0a%e2%80%a2+Vernalis+has+since+exercised+their+option+and+licensed+worldwide+rights+and+initiated+an+HSP90+joint+research+programme+with+Novartis%0d%0a%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+KuDOS%0d%0a%0d%0a%e2%80%a2+KuDOS+Pharmaceuticals%0d%0a%ef%83%98%0d%0a%0d%0aA+start+up+based+on+Prof.+Steve+Jackson%e2%80%9fs+Cancer+Research+UK+funded+work+at+the+University+of+Cambridge.%0d%0a%0d%0a%e2%80%a2+Financing%0d%0a%ef%83%98+%ef%83%98+%ef%83%98%0d%0a%0d%0a%ef%83%98%0d%0a%0d%0a1998+%e2%80%93+Incorporated+1999+%e2%80%93+1st+round+funding+2001+%e2%80%93+2nd+round+funding+2002+%e2%80%93+3rd+round+funding%0d%0a%0d%0a%c2%a3250%2c000+seed+funding+from+CRT+%c2%a35m+%c2%a38m+%c2%a329.5m+(one+of+the+largest+funding+rounds+in+Europe+in+2002)%0d%0a%0d%0a%e2%80%a2+Investment+from%3a%0d%0aAdvent+Venture+Partners+LSP+Life+Sciences+Partners+BankInvest+Biomedical+Venture+Johnson%26Johnson+Development+Corporation%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0aSchroder+Ventures+Life+Sciences+Euclid+SR+Partners+3i+Group%0d%0a%0d%0a%0cCancer+Research+Technology%0d%0a%0d%0aCase+Study%3a+KuDOS%0d%0a%0d%0aCRT%e2%80%9fs+role+%e2%80%a2+Frequent+contact+with+Prof+Jackson+to+discuss+his+research+%e2%80%a2+CRT+filed+5+patents+and+took+assignment+from+the+University+%e2%80%a2+Reviewing+the+commercial+strategy+revealed+start+up+potential%0d%0a%ef%83%98+%ef%83%98%0d%0a%0d%0aFirst+class+scientist+committed+to+developing+the+technology+Strong+intellectual+property+portfolio%0d%0a%0d%0a%e2%80%a2+Prepared+a+business+plan+for+the+company%0d%0a%e2%80%a2+Incorporated+the+company+and+CRT+provided+%c2%a3250k+seed+investment+%e2%80%a2+Presented+the+commercialisation+package+to+VCs+%e2%80%a2+First+round+funding+secured+from+Schroders%2fAdvent%2f3i+%e2%80%a2+Negotiated+the+relevant+agreement+i.e.+FSA+plus+others+%e2%80%a2+CRT+took+a+position+on+the+board%0d%0aLeading+Technology+Transfer+and+Development+in+Oncology%0d%0a%0d%0a%0c